Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines–Heart Failure (GWTG-HF) Registry

IMPORTANCE: In May 2020, dapagliflozin was approved by the US Food and Drug Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction (HFrEF), based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) tr...

全面介紹

Na minha lista:
書目詳細資料
發表在:JAMA Cardiol
Main Authors: Vaduganathan, Muthiah, Greene, Stephen J., Zhang, Shuaiqi, Grau-Sepulveda, Maria, DeVore, Adam D., Butler, Javed, Heidenreich, Paul A., Huang, Joanna C., Kittleson, Michelle M., Joynt Maddox, Karen E., McDermott, James J., Owens, Anjali Tiku, Peterson, Pamela N., Solomon, Scott D., Vardeny, Orly, Yancy, Clyde W., Fonarow, Gregg C.
格式: Artigo
語言:Inglês
出版: American Medical Association 2020
主題:
Original Investigation
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666432/
https://ncbi.nlm.nih.gov/pubmed/33185662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.5864
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍